

**Manuscript title:** MD1003 (high dose Pharmaceutical grade Biotin) for the treatment of chronic visual loss related to optic neuritis in multiple sclerosis: A randomized, double-blind, placebo-controlled study

**Journal:** CNS Drugs

**Authors:** Ayman Tourbah, Olivier Gout, Alain Vighetto, Véronique Deburghgraeve, Jean Pelletier, Caroline Papeix, Christine Lebrun-Frenay, Pierre Labauge, David Brassat, Ahmed Toosy, David-Axel Laplaud, Olivier Outteryck, Thibault Moreau, Marc Debouverie, Pierre Clavelou, Olivier Heinzlef, Jérôme De Sèze, Gilles Defer, Frédéric Sedel, Carl Arndt

**Corresponding author:** Professor Ayman Tourbah, Department of Neurology and Faculty of Medicine, CHU de Reims, and UCRA, Reims, France, LPN EA 2027 Université Paris 8, Saint-Denis. Email: [atourbah@chu-reims.fr](mailto:atourbah@chu-reims.fr)

### Online Resources 1. MS-ON study design

#### Study Design

A 6-month double-blind, randomized, placebo-controlled study with two arms (placebo, MD1003 [biotin 300 mg/day]). The study will be followed by a 6-month extension phase during which all patients will receive MD1003.

- 93 adult MS patients with chronic visual loss resulting from MS
- Uni- or bi-lateral optic neuropathy (visual acuity below 0.5 decimal chart) confirmed at 6 months

